The United States Patent and Trademark Office (USPTO) has published patent application US20260083719A1, filed by The University of Adelaide. This application, filed on December 1, 2025, discloses methods and products for improving sperm quality and fertility, specifically by exposing sperm to BGP-15 or its derivatives. The application also covers the use of such improved sperm in assisted reproductive technologies.

While this is a patent application and not a regulation imposing direct compliance obligations, it signals potential future developments in fertility treatments and related products. Companies in the pharmaceutical and biotechnology sectors, particularly those involved in reproductive health or drug development for male infertility, should monitor this application's progress and any subsequent granted patents. The abstract suggests potential applications in assisted reproductive technologies, which may impact clinical practices and product development strategies.